Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer: Interdiscip Int J Am Cancer Soc. 2007;109:455–64.

Article  CAS  Google Scholar 

Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46.

Article  CAS  PubMed  Google Scholar 

Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol. 2020;38:3947–70.

Article  CAS  PubMed  Google Scholar 

Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17:367–402.

Article  CAS  Google Scholar 

Keilholz U, Ascierto PA, Dummer R, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31:1435–48.

Article  CAS  PubMed  Google Scholar 

Ascierto PA, Dréno B, Larkin J, et al. 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation–positive advanced melanoma: extended follow-up of the coBRIM study. Clin Cancer Res. 2021;27:5225–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dummer R, Flaherty KT, Robert C, et al. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma. J Clin Oncol 2022:JCO.21.02659.

Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626–36.

Article  CAS  PubMed  Google Scholar 

Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2000:CD001215.

Huncharek M, Caubet JF, McGarry R0. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res. 2001;11:75–81.

Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist. 2007;12:1114–23.

Article  CAS  PubMed  Google Scholar 

Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-.

Article  CAS  PubMed  Google Scholar 

Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22:1118–25.

Article  CAS  PubMed  Google Scholar 

Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990;66:1873–8.

Article  CAS  PubMed  Google Scholar 

Wiernik PH, Einzig AI. Taxol in malignant melanoma. J Natl Cancer Inst Monogr. 1993;15:185–7.

Google Scholar 

Einzig AI, Hochster H, Wiernik PH, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs. 1991;9:59–64.

Article  CAS  PubMed  Google Scholar 

Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of taxol in metastatic melanoma. Cancer. 1990;65:2478–81.

Article  CAS  PubMed  Google Scholar 

O’Day S, Gonzalez R, Lawson D, et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol. 2009;27:5452–8.

Article  CAS  PubMed  Google Scholar 

Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res. 2004;14:63–6.

Article  CAS  PubMed  Google Scholar 

Walker L, Schalch H, King DM, Dietrich L, Eastman M, Kwak M, Kim K, Albertini MR. Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res. 2005;15:453–9.

Hersh EM, Del Vecchio M, Brown MP, et al. A randomized, controlled phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Ann Oncol. 2015;26:2267–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bedikian AY, DeConti RC, Conry R, et al. Phase 3 study of docosahexaenoic acid–paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol. 2011;22:787–93.

Article  CAS  PubMed  Google Scholar 

Bedikian AY, Weiss GR, Legha SS, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol. 1995;13:2895–9.

Article  CAS  PubMed  Google Scholar 

Einzig AI, Schuchter LM, Recio A, Coatsworth S, Rodriquez R, Wiernik PH. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med Oncol. 1996;13:111–7.

Article  CAS  PubMed  Google Scholar 

Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer. 1994;30:1061–4.

Article  Google Scholar 

Kirkwood JM, Agarwala SS. Systemic cytotoxic and biologic therapy of melanoma. PPO Updates. 1993;7:1993–2016.

Google Scholar 

Glover D, Ibrahim J, Kirkwood J, et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res. 2003;13:619–26.

Article  CAS  PubMed  Google Scholar 

Evans LM, Casper ES, Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma 1, 2. Cancer Treat Rep. 1987;71:171.

CAS  PubMed  Google Scholar 

Güven K, Kittler H, Wolff K, Pehamberger H. Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients. Melanoma Res. 2001;11:411–5.

Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer: Interdiscip Int J Am Cancer Soc. 2006;106:375–82.

Article  CAS  Google Scholar 

Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002;25:283–6.

Article  PubMed  Google Scholar 

Flaherty KT, Lee SJ, Zhao F, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013;31:373.

Article  CAS  PubMed  Google Scholar 

Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-.

Article  CAS  PubMed  Google Scholar 

Hofmann MA, Hauschild A, Mohr P, Garbe C, Weichenthal M, Trefzer U, Drecoll U, Tilgen W, Schadendorf D, Kaatz M, Ulrich J. Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient’s choice: a multicentre Dermatologic Cooperative Oncology Group trial. Melanoma Res. 2011;21:516–23.

Seigler HF, Lucas VS Jr, Pickett NJ, Huang AT. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer. 1980;46:2346–8.

Article  CAS  PubMed  Google Scholar 

Vuoristo M-S, Hahka-Kemppinen M, Parvinen L-M, et al. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-α in patients with advanced melanoma. Melanoma Res. 2005;15:291–6.

Article  CAS  PubMed  Google Scholar 

Eggermont AMM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004;40:1825–36.

Article  CAS  PubMed  Google Scholar 

Wilson MA, Schuchter LM. Chemotherapy for melanoma. In: Kaufman HL, Mehnert JM, editors. Melanoma. Cham: Springer International Publishing; 2016. p. 209–29.

Chapter  Google Scholar 

Bajetta E, Del Vecchio M, Bernard-Marty C, et al. Metastatic melanoma: chemotherapy. Semin Oncol. 2002;29:427–45.

Article  CAS  PubMed  Google Scholar 

Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004;22:2101–7.

Article  CAS  PubMed  Google Scholar 

Paul MJ, Summers Y, Calvert AH, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002;12.

Silverman RB, Holladay MW. The organic chemistry of drug design and drug action. Academic press. 2014.

Long HJ. Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin Proc. 1994;69:341–5. 

Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263–8.

Article  CAS  PubMed  Google Scholar 

Yamamoto Y, Kawano I, Iwase H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther. 2011;4:123.